Roche Reports the P-I (CT-996-201) Study Data of CT-996 for Treating Obesity
Shots:
- The P-I (CT-996-201) study assesses SAD & MAD of CT-996 vs PBO in otherwise-healthy adults, with part 1 involving 40 obese subjects (completed), part 2 involving 25 obese subjects without T2D (completed) & part 3 involving 30 obese subjects with T2D (anticipated in Q4’24)
- Topline data from the 2 arms depicted a mean weight loss of -6.1% among obese individuals without T2D in 4wks. while a weight loss of -7.3% vs -1.2% was observed post 4wks. with PK data suggesting QD oral dosing
- Safety was well-tolerated, aligned with incretin drugs & did not lead to treatment discontinuations; blood levels of CT-996 were stable regardless of fasting or high-fat meals. It will advance to P-II based on these results
Ref: Roche | Image: Roche
Related News:- Roche’s Accu-Chek SmartGuide CGM System Gains CE Mark for Diabetic Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
